Pancreatic Cancer Research

ResearcherUniversity College DublinActive in the last 2 years

Oonagh M. Griffin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2326-3009; OpenAlex author ID A5083940972. Sources: ClinicalTrials.gov.

Their work

Papers
9
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 trial · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. Development of a Core Outcome Set for Pancreatic Cancer Rehabilitation – A Study Protocol Co-author DOI 10.12688/hrbopenres.14558.1↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  4. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  5. Recent Advances in Pancreatic Ductal Adenocarcinoma: Strategies to Optimise the Perioperative Nutritional Status in Pancreatoduodenectomy Patients. Co-author DOI 10.3390/cancers15092466↗
  6. Measurement of Body Composition in Pancreatic Cancer: A Systematic Review, Meta-Analysis, and Recommendations for Future Study Design. Co-author DOI 10.1159/000524575↗
  7. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  8. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.07.039↗
  9. Sarcopenia-A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.1006↗

Trials 1

  1. Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial) Principal investigator NCT06149546↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ray McDermott · 1 shared paper, 1 shared trial, 2019–2024 · strength 0.80
  2. Kevin C. Conlon · 5 shared papers, 2018–2025 · strength 0.67
  3. Keith John Roberts · 3 shared papers, 2020–2025 · strength 0.43
  4. Linda M. O’Neill · 1 shared paper, 2026 · strength 0.29
  5. Lisa Brennan · 1 shared paper, 2026 · strength 0.29
  6. Grainne Mary O'Kane · 1 shared paper, 2026 · strength 0.29
  7. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  8. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  9. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  10. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  11. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  12. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  13. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.22
  14. Johan Gagnière · 2 shared papers, 2020–2025 · strength 0.22
  15. Stijn R. van Roessel · 2 shared papers, 2020–2025 · strength 0.22
  16. Frederik Christiaan Berrevoet · 2 shared papers, 2020–2025 · strength 0.22
  17. Eran van Veldhuisen · 2 shared papers, 2020–2025 · strength 0.22
  18. Thilo Hackert · 2 shared papers, 2020–2025 · strength 0.22
  19. Isabella M. Frigerio · 2 shared papers, 2020–2025 · strength 0.22
  20. Giovanni Butturini · 2 shared papers, 2020–2025 · strength 0.22
  21. Quisette P. Janssen · 2 shared papers, 2020–2025 · strength 0.22
  22. Hanneke W.M. van Laarhoven · 2 shared papers, 2020–2025 · strength 0.22
  23. Bas Groot Koerkamp · 2 shared papers, 2020–2025 · strength 0.22
  24. Rupaly Pandé · 2 shared papers, 2020–2025 · strength 0.22
  25. Mickaël Lesurtel · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.